PVI
ACHN

Pura Vida Investments’s Achillion Pharmaceuticals ACHN Stock Holding History

Pura Vida Investments’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-566,600
Closed -$2.04M – 138
2019
Q3 		$2.04M Buy
+566,600
New +$2.18M 0.35% 66

Other funds holding ACHN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pura Vida Investments's ACHN Position: Q4 2019 in Review

Pura Vida Investments sold out of Achillion Pharmaceuticals (ACHN) in Q4 2019, closing a stake of 566,600 shares — an estimated $2.04M sold.

Pura Vida Investments first reported a position in ACHN in Q3 2019 and held it in 1 quarter. The position peaked at $2.04M in Q3 2019. 132 funds tracked by Wall St. Rank hold ACHN as of Q4 2019.

  • Pura Vida Investments reported no remaining Achillion Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Pura Vida Investments sold 566,600 Achillion Pharmaceuticals shares in Q4 2019, an estimated $2.04M.
  • Pura Vida Investments first reported a position in Achillion Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Pura Vida Investments's Achillion Pharmaceuticals position peaked at $2.04M in Q3 2019.
  • 132 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2019.

Based on Pura Vida Investments's 13F filing for Q4 2019, filed 14 Feb 2020.